IIB_osteosarcoma._Current_management,_local_control,_and_survival_statistics--Sao_Paulo,_Brazil._Ninety-two_patients_with_IIB_osteosarcoma_of_the_extremities_were_treated_with_intraarterial_(IA)_cisplatinum_(CDDP)_followed_by_surgery_amputation_(61.6%)_or_resection_with_endoprosthesis_(38.4%)._Postoperative_chemotherapy_alternating_adriamycin_and_CDDP_was_used._The_total_three-year_survival_was_62.1%,_and_the_disease-free_survival_was_41.1%._The_pathologic_evaluation_of_the_degree_of_tumor_necrosis_in_response_to_the_IA_CDDP_showed_that_in_53.2%,_the_necrosis_was_over_90%._The_multivariate_analysis_of_prognostic_factors_has_shown_that_the_highest_survival_was_among_females_with_tumors_smaller_than_15_cm._Patients_with_lesions_equal_to_or_larger_than_15_cm_were_three_times_as_likely_to_die_of_the_disease._A_second,_more_aggressive_study_is_now_underway,_in_which_high_dose_methotrexate_(HDMTX)_is_preoperatively_combined_with_adriamycin_and_CDDP._Following_operation,_ifosfamide_is_added_to_the_cases_with_a_smaller_degree_of_tumor_necrosis,_while_the_other_group_of_patients_will_continue_with_HDMTX,_in_addition_to_CDDP_and_adriamycin_(these_last_two_drugs_are_used_in_both_arms)._Until_now,_complete_remission_has_been_achieved_in_82%_and_86%,_respectively,_with_a_follow-up_examination_varying_from_four_to_26_months_(average,_14_months)._This_is_of_extreme_importance,_because_the_majority_of_the_authors'_patients_have_tumors_at_initial_evaluation_larger_than_10_cm_in_diameter.